Bifogade filer
PDF
Kurs
-12,64%
Likviditet
4,13 MSEK
Kalender
| Est. tid* | ||
| 2025-05-21 | N/A | X-dag ordinarie utdelning SYNT 0.00 SEK |
| 2025-05-20 | N/A | Årsstämma |
| 2025-05-20 | 08:40 | Kvartalsrapport 2025-Q1 |
| 2025-02-25 | - | Bokslutskommuniké 2024 |
| 2024-12-17 | - | Extra Bolagsstämma 2024 |
| 2024-11-19 | - | Kvartalsrapport 2024-Q3 |
| 2024-08-27 | - | Kvartalsrapport 2024-Q2 |
| 2024-05-22 | - | X-dag ordinarie utdelning SYNT 0.00 SEK |
| 2024-05-21 | - | Årsstämma |
| 2024-05-21 | - | Kvartalsrapport 2024-Q1 |
| 2024-02-20 | - | Bokslutskommuniké 2023 |
| 2023-11-10 | - | Kvartalsrapport 2023-Q3 |
| 2023-08-22 | - | Kvartalsrapport 2023-Q2 |
| 2023-05-24 | - | X-dag ordinarie utdelning SYNT 0.00 SEK |
| 2023-05-23 | - | Årsstämma |
| 2023-05-23 | - | Kvartalsrapport 2023-Q1 |
| 2023-02-15 | - | Bokslutskommuniké 2022 |
| 2022-11-16 | - | Kvartalsrapport 2022-Q3 |
| 2022-08-23 | - | Kvartalsrapport 2022-Q2 |
| 2022-05-11 | - | X-dag ordinarie utdelning SYNT 0.00 SEK |
| 2022-05-10 | - | Årsstämma |
| 2022-05-10 | - | Kvartalsrapport 2022-Q1 |
| 2022-03-29 | - | Extra Bolagsstämma 2022 |
| 2022-02-22 | - | Bokslutskommuniké 2021 |
| 2021-11-11 | - | Kvartalsrapport 2021-Q3 |
| 2021-07-13 | - | Kvartalsrapport 2021-Q2 |
| 2021-05-20 | - | Split SYNT 1:10 |
| 2021-05-12 | - | X-dag ordinarie utdelning SYNT 0.00 SEK |
| 2021-05-11 | - | Årsstämma |
| 2021-05-11 | - | Kvartalsrapport 2021-Q1 |
| 2021-02-18 | - | Bokslutskommuniké 2020 |
| 2020-11-12 | - | Kvartalsrapport 2020-Q3 |
| 2020-10-02 | - | X-dag ordinarie utdelning SYNT 1.50 SEK |
| 2020-07-14 | - | Kvartalsrapport 2020-Q2 |
| 2020-05-05 | - | Årsstämma |
| 2020-05-05 | - | Kvartalsrapport 2020-Q1 |
| 2020-02-27 | - | Bokslutskommuniké 2019 |
| 2019-11-12 | - | Kvartalsrapport 2019-Q3 |
| 2019-07-14 | - | Kvartalsrapport 2019-Q2 |
| 2019-04-30 | - | X-dag ordinarie utdelning SYNT 1.50 SEK |
| 2019-04-29 | - | Årsstämma |
| 2019-04-29 | - | Kvartalsrapport 2019-Q1 |
| 2019-02-27 | - | Bokslutskommuniké 2018 |
| 2018-11-16 | - | Kvartalsrapport 2018-Q3 |
| 2018-08-22 | - | Kvartalsrapport 2018-Q2 |
| 2018-04-26 | - | X-dag ordinarie utdelning SYNT 0.00 SEK |
| 2018-04-25 | - | Årsstämma |
| 2018-04-25 | - | Kvartalsrapport 2018-Q1 |
| 2018-02-21 | - | Bokslutskommuniké 2017 |
| 2017-11-10 | - | Kvartalsrapport 2017-Q3 |
| 2017-08-24 | - | Kvartalsrapport 2017-Q2 |
| 2017-04-26 | - | X-dag ordinarie utdelning SYNT 0.00 SEK |
| 2017-04-25 | - | Årsstämma |
| 2017-04-25 | - | Kvartalsrapport 2017-Q1 |
| 2017-02-15 | - | Bokslutskommuniké 2016 |
| 2016-10-28 | - | Kvartalsrapport 2016-Q3 |
| 2016-08-26 | - | Kvartalsrapport 2016-Q2 |
| 2016-04-27 | - | X-dag ordinarie utdelning SYNT 0.00 SEK |
| 2016-04-26 | - | Årsstämma |
| 2016-04-26 | - | Kvartalsrapport 2016-Q1 |
| 2016-02-26 | - | Bokslutskommuniké 2015 |
| 2015-10-30 | - | Kvartalsrapport 2015-Q3 |
| 2015-08-28 | - | Kvartalsrapport 2015-Q2 |
| 2015-04-13 | - | Årsstämma |
| 2015-04-13 | - | Kvartalsrapport 2015-Q1 |
| 2015-02-17 | - | X-dag ordinarie utdelning SYNT 0.00 SEK |
| 2015-02-13 | - | Bokslutskommuniké 2014 |
| 2014-11-28 | - | Kvartalsrapport 2014-Q3 |
| 2014-09-26 | - | Extra Bolagsstämma 2014 |
| 2014-08-29 | - | Kvartalsrapport 2014-Q2 |
Beskrivning
| Land | Sverige |
|---|---|
| Lista | Spotlight |
| Sektor | Hälsovård |
| Industri | Medicinteknik |
There is a great interest in and demand for SyntheticMR's products in all priority markets. However, a number of purchasing processes with significant order values are delayed at the customer level, which affects the outcome in the quarter. The processes are still ongoing and the experience so far is that the restrictions are temporary and have no long-term impact.
Net sales for the first quarter 2022 are estimated to amount to approximately SEK 10 million (14.7). The figures are preliminary and unaudited. The full interim report for the first quarter will be published on May 10, 2022, as previously announced.
"As communicated earlier, our business sometimes have large fluctuations over the quarters. It is important to point out, however, that the response from the market for our offerings after the previous record quarter is unabated strong. My solid belief in the potential for the current and coming years is intact", says Ulrik Harrysson, CEO, SyntheticMR.
This disclosure contains information that SyntheticMR AB is obliged to make public pursuant to the EU Market Abuse Regulation (EU nr 596/2014). The information was submitted for publication, through the agency of the contact person, on 05-04-2022 18:26 CET.
For additional information, please contact Ulrik Harrysson, CEO, SyntheticMR AB, +46 70 529 29 87 ulrik.harrysson@syntheticmr.com.